Published in Eur J Epidemiol on September 20, 2006
Hepatitis B and HIV: prevalence, AIDS progression, response to highly active antiretroviral therapy and increased mortality in the EuroSIDA cohort. AIDS (2005) 4.40
Clinical relevance of hepatitis B viral mutations. Hepatology (2000) 2.03
Hepatitis B virus with antigenically altered hepatitis B surface antigen is selected by high-dose hepatitis B immune globulin after liver transplantation. Hepatology (1998) 1.98
Low genetic diversity despite hyperendemicity of hepatitis B virus genotype E throughout West Africa. J Infect Dis (2004) 1.65
HBV and HCV prevalence and viraemia in HIV-positive and HIV-negative pregnant women in Abidjan, Côte d'Ivoire: the ANRS 1236 study. J Med Virol (2004) 1.55
Human immunodeficiency virus type 2. J Gen Virol (2002) 1.50
Factors associated with clinical progression in HIV-2 infected-patients: the French ANRS cohort. AIDS (2003) 1.40
Analysis of HBs antigen negative variant of hepatitis B virus: unique substitutions, Glu129 to Asp and Gly145 to Ala in the surface antigen gene. Med Sci Monit (2001) 1.09
Polymorphism and drug-selected mutations in the reverse transcriptase gene of HIV-2 from patients living in southeastern France. J Med Virol (2005) 1.03
The prevalence of hepatitis B surface antigenaemia in HIV positive patients in the Niger Delta Nigeria. Niger J Med (2004) 1.00
Fulminant hepatitis B associated with a specific insertion in the basal core promoter region of hepatitis B virus DNA after immunosuppressive treatment. Clin Infect Dis (2005) 0.87
Ciclosporin versus infliximab in patients with severe ulcerative colitis refractory to intravenous steroids: a parallel, open-label randomised controlled trial. Lancet (2012) 5.12
Incidence of non-AIDS-defining cancers before and during the highly active antiretroviral therapy era in a cohort of human immunodeficiency virus-infected patients. J Clin Oncol (2003) 4.15
Molecular quantification of Gardnerella vaginalis and Atopobium vaginae loads to predict bacterial vaginosis. Clin Infect Dis (2008) 3.90
Early administration of azathioprine vs conventional management of Crohn's Disease: a randomized controlled trial. Gastroenterology (2013) 3.45
Monitoring bacterial community of human gut microbiota reveals an increase in Lactobacillus in obese patients and Methanogens in anorexic patients. PLoS One (2009) 3.18
Infliximab plus azathioprine for steroid-dependent Crohn's disease patients: a randomized placebo-controlled trial. Gastroenterology (2006) 2.91
Safety and efficacy of dolutegravir in treatment-experienced subjects with raltegravir-resistant HIV type 1 infection: 24-week results of the VIKING Study. J Infect Dis (2012) 2.43
High prevalence of Methanobrevibacter smithii and Methanosphaera stadtmanae detected in the human gut using an improved DNA detection protocol. PLoS One (2009) 2.05
Frequency, determinants and consequences of delayed access to care for HIV infection in France. Antivir Ther (2007) 1.83
The impact of methadone or buprenorphine treatment and ongoing injection on highly active antiretroviral therapy (HAART) adherence: evidence from the MANIF2000 cohort study. Addiction (2008) 1.76
Transfusion-associated hepatitis E, France. Emerg Infect Dis (2007) 1.66
Retention in opioid substitution treatment: a major predictor of long-term virological success for HIV-infected injection drug users receiving antiretroviral treatment. Clin Infect Dis (2009) 1.65
French national sentinel survey of antiretroviral drug resistance in patients with HIV-1 primary infection and in antiretroviral-naive chronically infected patients in 2001-2002. J Acquir Immune Defic Syndr (2005) 1.63
Primary liver cancer is more aggressive in HIV-HCV coinfection than in HCV infection. A prospective study (ANRS CO13 Hepavih and CO12 Cirvir). Clin Res Hepatol Gastroenterol (2011) 1.62
Long-term clinical and imaging follow-up of nonoperated branch duct form of intraductal papillary mucinous neoplasms of the pancreas. Pancreas (2012) 1.53
Evaluation of the genotypic prediction of HIV-1 coreceptor use versus a phenotypic assay and correlation with the virological response to maraviroc: the ANRS GenoTropism study. Antimicrob Agents Chemother (2010) 1.53
HIV-1 resistant strains acquired at the time of primary infection massively fuel the cellular reservoir and persist for lengthy periods of time. AIDS (2006) 1.45
Relapse of hepatitis C virus after 14 months of sustained virological response following pegylated-interferon alpha plus ribavirin therapy in a human immunodeficiency virus type 1 infected patient. J Clin Virol (2013) 1.44
Nonadherence among HIV-infected injecting drug users: the impact of social instability. J Acquir Immune Defic Syndr (2002) 1.41
Depression and clinical progression in HIV-infected drug users treated with highly active antiretroviral therapy. Antivir Ther (2005) 1.40
Prevalence of HIV-1 drug resistance in treated patients: a French nationwide study. J Acquir Immune Defic Syndr (2007) 1.35
Detection of Mycobacterium tuberculosis complex organisms in the stools of patients with pulmonary tuberculosis. Microbiology (2009) 1.34
The rhizome of the multidrug-resistant Enterobacter aerogenes genome reveals how new "killer bugs" are created because of a sympatric lifestyle. Mol Biol Evol (2012) 1.34
Villous atrophy induced by mycophenolate mofetil in renal-transplant patients. Transpl Int (2004) 1.31
DOC1R: a MAP kinase substrate that control microtubule organization of metaphase II mouse oocytes. Development (2003) 1.30
Efficacy and tolerability of a nucleoside reverse transcriptase inhibitor-sparing combination of lopinavir/ritonavir and efavirenz in HIV-1-infected patients. J Acquir Immune Defic Syndr (2005) 1.29
A large French prospective cohort of HIV-infected patients: the Nadis Cohort. HIV Med (2009) 1.29
Stable prevalence of genotypic drug resistance mutations but increase in non-B virus among patients with primary HIV-1 infection in France. AIDS (2003) 1.24
Risk factors of chronic kidney disease in HIV-infected patients. Clin J Am Soc Nephrol (2011) 1.21
Multiplex real-time PCR diagnostic of relapsing fevers in Africa. PLoS Negl Trop Dis (2013) 1.20
Treatment of severe acute hepatitis E by ribavirin. J Clin Virol (2011) 1.18
Genomic and phylogenetic analysis of hepatitis C virus isolates: a survey of 535 strains circulating in southern France. J Med Virol (2003) 1.16
Rapid and accurate bacterial identification in probiotics and yoghurts by MALDI-TOF mass spectrometry. J Food Sci (2011) 1.15
Genotypic determinants of the virological response to tenofovir disoproxil fumarate in nucleoside reverse transcriptase inhibitor-experienced patients. Antivir Ther (2004) 1.14
Autochthonous infections with hepatitis E virus genotype 4, France. Emerg Infect Dis (2012) 1.14
Increasing prevalence of transmitted drug resistance mutations and non-B subtype circulation in antiretroviral-naive chronically HIV-infected patients from 2001 to 2006/2007 in France. J Antimicrob Chemother (2010) 1.09
Therapeutic drug monitoring of lopinavir/ritonavir given alone or with a non-nucleoside reverse transcriptase inhibitor. Br J Clin Pharmacol (2004) 1.08
Natural presence of substitution R155K within hepatitis C virus NS3 protease from a treatment-naïve chronically infected patient. Hepatology (2008) 1.08
Luminal cathepsin g and protease-activated receptor 4: a duet involved in alterations of the colonic epithelial barrier in ulcerative colitis. Am J Pathol (2009) 1.08
Etravirine-raltegravir, a marked interaction in HIV-1-infected patients: about four cases. AIDS (2009) 1.06
Peroral transgastric/transduodenal necrosectomy: success in the treatment of infected pancreatic necrosis. Ann Surg (2008) 1.05
Response to HAART in French patients with resistant HIV-1 treated at primary infection: ANRS Resistance Network. Antivir Ther (2007) 1.04
Stable frequency of HIV-1 transmitted drug resistance in patients at the time of primary infection over 1996-2006 in France. AIDS (2009) 1.04
Polymorphism and drug-selected mutations in the reverse transcriptase gene of HIV-2 from patients living in southeastern France. J Med Virol (2005) 1.03
Hepatitis E in an HIV-infected patient. J Clin Virol (2009) 1.03
HIV-associated Hodgkin lymphoma during the first months on combination antiretroviral therapy. Blood (2011) 1.02
The spectrum of malignancies in HIV-infected patients in 2006 in France: the ONCOVIH study. Int J Cancer (2011) 1.00
Hepatitis E associated with surgical training on pigs. Lancet (2007) 0.99
Effects of antiretroviral drug combinations on the differentiation of adipocytes. AIDS (2002) 0.99
Hepatitis E virus infection in patients infected with the human immunodeficiency virus. J Med Virol (2011) 0.99
Neurologic disorders and hepatitis E, France, 2010. Emerg Infect Dis (2011) 0.99
Minimal effect of MDR1 and CYP3A5 genetic polymorphisms on the pharmacokinetics of indinavir in HIV-infected patients. Br J Clin Pharmacol (2007) 0.98
Transmission of hepatitis C virus between hemodialysis patients sharing the same machine. Infect Control Hosp Epidemiol (2004) 0.98
Drug injection cessation among HIV-infected injecting drug users. Addict Behav (2004) 0.98
Sleep apnea is associated with bronchial inflammation and continuous positive airway pressure-induced airway hyperresponsiveness. J Allergy Clin Immunol (2007) 0.98
Human immunodeficiency virus infection and non-small cell lung cancer: survival and toxicity of antineoplastic chemotherapy in a cohort study. J Thorac Oncol (2011) 0.97
High indinavir Cmin is associated with higher toxicity in patients on indinavir-ritonavir 800/100 mg twice-daily regimen. J Acquir Immune Defic Syndr (2002) 0.97
Immunogenicity and safety of an HIV-1 lipopeptide vaccine in healthy adults: a phase 2 placebo-controlled ANRS trial. AIDS (2010) 0.97
Is Crohn's creeping fat an adipose tissue? Inflamm Bowel Dis (2011) 0.96
Cohort Profile: French hospital database on HIV (FHDH-ANRS CO4). Int J Epidemiol (2014) 0.96
Characterization of the poly(A) binding proteins expressed during oogenesis and early development of Xenopus laevis. Biol Cell (2002) 0.94
Simplification therapy with once-daily emtricitabine, didanosine, and efavirenz in HIV-1-infected adults with viral suppression receiving a protease inhibitor-based regimen: a randomized trial. J Infect Dis (2005) 0.93
Clinical and virological significance of the co-existence of HBsAg and anti-HBs antibodies in hepatitis B chronic carriers. Virology (2007) 0.93
Frequent transmission of hepatitis E virus among piglets in farms in Southern France. J Med Virol (2009) 0.93
Antiretroviral therapy does not block the secretion of the human immunodeficiency virus tat protein. Infect Disord Drug Targets (2012) 0.92
Factors associated with virological response to etravirine in nonnucleoside reverse transcriptase inhibitor-experienced HIV-1-infected patients. Antimicrob Agents Chemother (2009) 0.91
Severe transient neutropenia associated with acute human immunodeficiency virus type 1 infection. Eur J Intern Med (2005) 0.91
Infection with hepatitis E virus in kidney transplant recipients in southeastern France. J Med Virol (2012) 0.90
Raltegravir, etravirine and r-darunavir combination in adolescents with multidrug-resistant virus. AIDS (2009) 0.90
Age-related prevalence of Methanomassiliicoccus luminyensis in the human gut microbiome. APMIS (2012) 0.90
The French national prospective cohort of patients co-infected with HIV and HCV (ANRS CO13 HEPAVIH): early findings, 2006-2010. BMC Infect Dis (2010) 0.89
Risk factors for osteonecrosis in HIV-infected patients: impact of treatment with combination antiretroviral therapy. AIDS (2006) 0.89
Lack of correlation between the size of HIV proviral DNA reservoir and the level of immune activation in HIV-infected patients with a sustained undetectable HIV viral load for 10 years. J Clin Virol (2013) 0.89
The genotypic inhibitory quotient: a predictive factor of atazanavir response in HIV-1-infected treatment-experienced patients. J Acquir Immune Defic Syndr (2008) 0.89
Impact of hepatitis C virus coinfection on T-cell dynamics in long-term HIV-suppressors under combined antiretroviral therapy. AIDS (2015) 0.88
Entecavir as a first-line treatment for HBV reactivation following polychemotherapy for lymphoma. Br J Haematol (2008) 0.88
Long-term effects of intermittent interleukin-2 therapy in chronic HIV-infected patients (ANRS 048-079 Trials). AIDS (2007) 0.88
Unique NS5b hepatitis C virus gene sequence consensus database is essential for standardization of genotype determinations in multicenter epidemiological studies. J Clin Microbiol (2006) 0.88
Significance of HPV 16 and 18 viral load quantitation in women referred for colposcopy. J Med Virol (2012) 0.87
Unusual selection of rtA181V HBV mutants cross-resistant to adefovir following prolonged lamivudine monotherapy: report of two cases. Antivir Ther (2006) 0.87